Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

NCT02590965 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.

NCT NCT02590965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02590965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Lead sponsor
Hutchison Medipharma Limited
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2014
Completion date
February 10, 2017
Enrollment
91 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer